Anti-pd-l1/anti-cd47 bispecific antibody
AssigneeBeijing Hanmi Pharmaceutical Co., Ltd.
InventorsJiawang Liu, Yaping Yang, Nanmeng Song, Maengsup Kim
Life of this patent
Estimating the term…
Abstract
Provided are an anti-PD-L1/anti-CD47 bispecific antibody that has natural IgG characteristics and is in a highly stable heterodimer form without the heavy chain and light chain being mismatched, and a preparation method therefor. Either the first Fc chain or second Fc chain of the bispecific antibody comprises amino acid substitutions at positions 366 and 399, and the other comprises amino acid substitutions at positions 351, 407 and 409.
Claims34
A bispecific antibody in the form of a heterodimer, which comprises a first Fc chain and a second Fc chain, and a first antigen-binding functional region that can specifically bind to PD-L1 and a second antigen-binding functional region that can specifically bind to CD47;
- wherein each of the first Fc chain and the second Fc chain is an immunoglobulin G Fc fragment comprising an amino acid substitution, and the first Fc chain and the second Fc chain together constitute a heterodimer that can bind to an Fc receptor;
- wherein the first Fc chain and the second Fc chain are linked to the first antigen-binding functional region and the second antigen-binding functional region by a covalent bond or a linker, respectively;
- and
- wherein either one of the first Fc chain and the second Fc chain comprises amino acid substitutions at positions 366 and 399, and the other comprises amino acid substitutions at positions 351, 407, and 409, wherein the amino acid positions are numbered according to Kabat EU Index numbering system.
Dependencies are inferred from the claim text.